Rational selection of a biomarker panel targeting unmet clinical needs in kidney injury.

ABSTRACT: The pipeline of biomarker translation from bench to bedside is challenging and limited biomarkers have been adopted to routine clinical care. Ideally, biomarker research and development should be driven by unmet clinical needs in health care. To guide researchers, clinical chemists and clinicians in their biomarker research, the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) has developed a structured questionnaire in which the clinical gaps in current clinical pathways are identified and desirable performance specifications are predefined. In kidney injury, the high prevalence of the syndrome acute kidney injury (AKI) in the hospital setting has a significant impact on morbidity, patient survival and health care costs, but the use of biomarkers indicating early k

SUBMITTER: van Duijl TT 

PROVIDER: S-EPMC7898424 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature